BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase II Trial Targeting Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc. announced that the final subject in its BRTX-100 Phase II clinical trial safety cohort has been dosed. Study participants were dosed at a 3:1 ratio with either BRTX-100 or control.